EXTERNAL SLT Treatment in Patients With Uncontrolled OPEN ANGLE GLAUCOMA

NCT ID: NCT01384149

Last Updated: 2014-08-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the advantages and disadvantages of external selective laser trabeculoplasty (SLT) in treating open angle glaucoma,compared to traditional SLT.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

glaucoma is the 2nd leading cause for blindness in the western world.at the time approximately 60 million people are diagnosed as glaucoma patients with an estimated rise of 30% in the next decade. glaucoma is defined as a progressive damage to the optic nerve ,followed by a damage to the visual field. high intraocular pressure (IOP) is considered a main risk factor.lowering IOP can be done in several ways ,including medication ,laser treatment and operations.

medical treatment is effective in most cases ,but requires high daily compliance,side effects and availability of medication in living areas.

laser trabeculoplasty treatment for reducing IOP is a first line treatment for patients with open angle glaucoma (OAG).with success rate of 70-90%, it can be done as an additive treatment or as a sole treatment.

SLT or "cold" laser is a non-invasive treatment in which short wave lengths are being transduced in short intervals ,through a gonioscopic lens to the area of filtering angle. thec wave length is specific to cells rich in melanin (located in the filtering angle). the mechanism of action is regeneration of cytokine surge -causing macrophages recruitment and breakage of inter-cell connections at the trabecular meshwork (filtering area) and allows rise in fluid shift. the treatment requires several lasering to areas at the surrounding the wave does not cause rise in tissue heat or scaring of tissue and can be repeated.among its disadvantages are reduction in affect during time,causing new elevation of IOP , potential peripheral anterior synechia (PAS), corneal erosion or oedema,requires experience in treating through gonioscopic lense.

previous reports in the literature regarding external low intensity laser (LIL)show less complication rate.

our study evaluates the use of external SLT by using a standard retinal laser machine ,with procedure performed on the outer sclera-above the trabecular meshwork with laser parameters similar to those used in retinal surgeries.

this is a prospective, randomized, comparative clinical trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Open Angle Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

standart slt

gonioscopic selective laser trabeculoplasty

Group Type ACTIVE_COMPARATOR

standard slt

Intervention Type DEVICE

Nd:YAG LASER SLT gonioscopic laser treatment

external slt

perilimbal ,above trabecular meshwork 180 degrees ,100 laser dots

Group Type EXPERIMENTAL

external slt

Intervention Type DEVICE

Nd:YAG LASER SLT perilimbal above trabecular meshwork 180 degrees ,100 lasering dots

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

external slt

Nd:YAG LASER SLT perilimbal above trabecular meshwork 180 degrees ,100 lasering dots

Intervention Type DEVICE

standard slt

Nd:YAG LASER SLT gonioscopic laser treatment

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

external SLT laser SLT laser

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary Open Angle Glaucoma
* clinical appearance of pigment at the angle
* angle assessed as \>3 by a professional glaucoma expert
* IOP above target pressure under full anti-hypertensive treatment with a good compliance for treatment or IOP above target pressure and poor compliance to medical treatment due to: allergic reaction , side effects,physical inability etc.
* able to sign independently on an informed concent

Exclusion Criteria

* pregnancy/breast feeding
* glaucoma not specified as primary open angle glaucoma
* sensitivity to on or more of the medications in the study
* current /past intraocular inflammation
* primary open angle glaucoma with out appearance of pigment at the angle
* s/p laser trabeculoplasty at treatment eye
* inability to sign an informed concent
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Meir Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Noa Gefen, Dr.

Role: STUDY_CHAIR

Meir Medical Center, Kfar Saba, Israel

Michael Belkin, Prof.

Role: PRINCIPAL_INVESTIGATOR

Sheba Medical Center, Ramat Gan ,Israel

Ehud Asia, Prof.

Role: PRINCIPAL_INVESTIGATOR

Meir Medical Center, Kfar Saba, Israel

Audry masas-kaplan, Dr.

Role: PRINCIPAL_INVESTIGATOR

Assaf Harofhe Medical Center, Beer Yaakov, Israel

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Assaf Harofhe Medical Center

Beer Yaakov, , Israel

Site Status

Ophthalmology Department ,Meir Medical Center

Kfar Saba, , Israel

Site Status

Sheba Medical Center

Ramat Gan, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

References

Explore related publications, articles, or registry entries linked to this study.

Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006 Mar;90(3):262-7. doi: 10.1136/bjo.2005.081224.

Reference Type BACKGROUND
PMID: 16488940 (View on PubMed)

The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol. 2000 Oct;130(4):429-40. doi: 10.1016/s0002-9394(00)00538-9.

Reference Type BACKGROUND
PMID: 11024415 (View on PubMed)

Freeman EE, Munoz B, West SK, Jampel HD, Friedman DS. Glaucoma and quality of life: the Salisbury Eye Evaluation. Ophthalmology. 2008 Feb;115(2):233-8. doi: 10.1016/j.ophtha.2007.04.050. Epub 2007 Jul 26.

Reference Type BACKGROUND
PMID: 17655930 (View on PubMed)

Worthen DM, Wickham MG. Argon laser trabeculotomy. Trans Am Acad Ophthalmol Otolaryngol. 1974 Mar-Apr;78(2):OP371-5. No abstract available.

Reference Type BACKGROUND
PMID: 4856873 (View on PubMed)

Latina MA, Sibayan SA, Shin DH, Noecker RJ, Marcellino G. Q-switched 532-nm Nd:YAG laser trabeculoplasty (selective laser trabeculoplasty): a multicenter, pilot, clinical study. Ophthalmology. 1998 Nov;105(11):2082-8; discussion 2089-90. doi: 10.1016/S0161-6420(98)91129-0.

Reference Type BACKGROUND
PMID: 9818610 (View on PubMed)

Alvarado JA, Katz LJ, Trivedi S, Shifera AS. Monocyte modulation of aqueous outflow and recruitment to the trabecular meshwork following selective laser trabeculoplasty. Arch Ophthalmol. 2010 Jun;128(6):731-7. doi: 10.1001/archophthalmol.2010.85.

Reference Type BACKGROUND
PMID: 20547951 (View on PubMed)

Rachmiel R, Trope GE, Chipman ML, Gouws P, Buys YM. Laser trabeculoplasty trends with the introduction of new medical treatments and selective laser trabeculoplasty. J Glaucoma. 2006 Aug;15(4):306-9. doi: 10.1097/01.ijg.0000212233.11287.b3.

Reference Type BACKGROUND
PMID: 16865007 (View on PubMed)

Coleman AL, Yu F, Evans SJ. Use of gonioscopy in medicare beneficiaries before glaucoma surgery. J Glaucoma. 2006 Dec;15(6):486-93. doi: 10.1097/01.ijg.0000212287.62798.8f.

Reference Type BACKGROUND
PMID: 17106360 (View on PubMed)

Ivandic BT, Hoque NN, Ivandic T. Early diagnosis of ocular hypertension using a low-intensity laser irradiation test. Photomed Laser Surg. 2009 Aug;27(4):571-5. doi: 10.1089/pho.2008.2342.

Reference Type BACKGROUND
PMID: 19514814 (View on PubMed)

Framme C, Walter A, Prahs P, Theisen-Kunde D, Brinkmann R. Comparison of threshold irradiances and online dosimetry for selective retina treatment (SRT) in patients treated with 200 nanoseconds and 1.7 microseconds laser pulses. Lasers Surg Med. 2008 Nov;40(9):616-24. doi: 10.1002/lsm.20685.

Reference Type BACKGROUND
PMID: 18951425 (View on PubMed)

Klatt C, Saeger M, Oppermann T, Porksen E, Treumer F, Hillenkamp J, Fritzer E, Brinkmann R, Birngruber R, Roider J. Selective retina therapy for acute central serous chorioretinopathy. Br J Ophthalmol. 2011 Jan;95(1):83-8. doi: 10.1136/bjo.2009.178327. Epub 2010 Jun 15.

Reference Type BACKGROUND
PMID: 20554506 (View on PubMed)

Rolim-de-Moura CR, Paranhos A Jr, Loutfi M, Burton D, Wormald R, Evans JR. Laser trabeculoplasty for open-angle glaucoma and ocular hypertension. Cochrane Database Syst Rev. 2022 Aug 9;8(8):CD003919. doi: 10.1002/14651858.CD003919.pub3.

Reference Type DERIVED
PMID: 35943114 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

meirslt2011

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.